Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Integrating cognitive function into a cardiovascular (CV) framework can help with guiding polypharmacy, deprescribing support, early capacity assessment, advance care planning, and delirium screening.”
This ESC consensus statement provides a pragmatic, multidisciplinary framework for managing polypharmacy in heart failure patients to minimize adverse reactions and improve adherence.
The multiplicity of coexisting comorbidities affecting patients with heart failure ( HF) , together with the availability of multiple treatments improving prognosis in HF with reduced ejection fraction, has led to an increase in the number of prescribed medications to each patient. Polypharmacy is defined as the regular use of multiple medications, and over the last years has become an emerging aspect of HF care, particularly in older and frailer patients who are more frequently on multiple treatments, and are therefore more likely exposed to tolerability issues, drug–drug interactions and practical difficulties in management. Polypharmacy negatively affects adherence to treatment, and is associated with a higher risk of adverse drug reactions, impaired quality of life, more hospitalizations and worse prognosis. It is important to adopt and implement strategies for the management of polypharmacy from other medical disciplines, including medication reconciliation, therapeutic revision and treatment prioritization. It is also essential to develop new HF ‐specific strategies, with the primary goal of avoiding the use of redundant treatments, minimizing adverse drug reactions and interactions, and finally improving adherence. This clinical consensus statement document from the Heart Failure Association of the European Society of Cardiology proposes a rationale, pragmatic and multidisciplinary approach to drug prescription in the current era of multimorbidity and ‘multi‐medication’ in HF .
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Stolfo et al. (2025) conducted a review in Heart failure. Polypharmacy management strategies was evaluated. A clinical consensus statement from the Heart Failure Association of the ESC proposes a pragmatic and multidisciplinary approach to managing polypharmacy in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: